Serum beta2-microglobulin levels in hepatitis B e antigen-negative chronic hepatitis B patients under long term lamivudine monotherapy: Relationship with virological breakthrough

Canadian Journal of Gastroenterology

Volumn 18, Issue 5, 2004, Pages 307-313

  Elefsiniotis, Ioannis S ^a,d   Scarmeas, Nikolaos ^b   Glynou, Irene ^c   Pantazis, Konstantinos D ^a   Kada, Helen ^c   Mavrogiannis, Christos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c HELENA VENIZELOU HOSPITAL   (Greece)

^d NONE   (Greece)

Author keywords

Beta2 microglobulin; Chronic hepatitis B; Lamivudine; Virological breakthrough

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA 2 MICROGLOBULIN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ERUPTION; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HISTOLOGY; HUMAN; INFECTION RISK; LONG TERM CARE; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; MONOTHERAPY; NONBIOLOGICAL MODEL; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; VIRUS INHIBITION;

EID: 3042549207     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/864292     Document Type: Article

References (37)

1. World Health Organization. The World Health Report. Geneva: World Health Organization, 1998.
2. Schalm SW, Thomas HB, Hadziyannis SJ. Chronic hepatitis B. Prog Liver Dis 1990;9:443-62.
3. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of e antigen in patients with chronic Hepatitis B infection. Lancet 1989;2:588-91.
4. Laras A, Koskinas J, Avgidis K, Hadziyannis SJ. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepat 1998;5:241-8.
5. Brunetto MR, Giarin M, Saracco G, et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993;105:845-50.
6. Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaionannou C. Interferon alpha-2b treatment of HbeAg-negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol 1990;11(Suppl 1):S133-6.
7. Lai CL, Chien RN, Leung NW, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
8. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/Hepatitis B DNA positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889-96.
9. Leung NWY, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001;33:1527-32.
10. Rizzetto M, Santantonio T, Buti M, et al. Benefits of extended lamivudine treatment in patients with HbeAg - negative/HBV DNA positive chronic hepatitis B [abstract]. Hepatology 2000;32:459A.
11. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long term lamivudine in HbeAg negative precore mutant HBV liver disease. Hepatology 2002;36:219-26.
12. Rizzetto M. Efficacy of lamivudine in HbeAg-negative chronic hepatitis B. J Med Virol 2002;66:435-51.
13. Malaguarnera M, Restuccia S, Di Fazio I, Zoccolo AM, Trovato BA, Pistone G. Serum beta2-microglobulin in chronic hepatitis C. Dig Dis Sci 1997;42:762-6.
14. Freni MA, Ajello A, Spadaro A, et al. Class I HLA antigens hepatic display and beta2-microglobulin serum values in chronic hepatitis C: Effect of treatment with recombinant alpha interferon. Hepatogastroenterology 1997;44:1295-301.
15. Quiroga JA, Martin J, Pardo M, Carreno V. Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-alpha. Dig Dis Sci 1994;39:2485-96.
16. Kumashiro R, Ide T, Sasaki M, et al. Interferon-gamma brings additive antiviral environment when combined with interferon-alpha in patients with chronic hepatitis C. Hepatol Res 2002;22:20-6.
17. Garcia-Buey L, Lopez-Botet M, Garcia-Sanchez A, et al. Variability in the expression of a beta2-microglobulin epitope on hepatocytes in chronic type C hepatitis on treatment with interferon. Hepatology 1993;17:372-82.
18. Wejstal R, Norkrans G, Weiland O, et al. Lymphocyte subsets and beta2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effects on interferon-alpha treatment. Clin Exp Immunol 1992;87:340-5.
19. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
20. World Health Organization. Laboratory Biosafety Manual. Geneva: World Health Organization, 1993.
21. Lawless J. Statistical Model and Methods for Lifetime Data. New York: John Wiley Sons Inc, 1982.
22. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrica 1986;73:13-22.
23. Hadziyannis SJ, Papatheodoridis GV, Dimon E, Laras A, Papioannou C. Efficacy of long term lamivudine monotherapy in patients with hepatitis B e antigen negative chronic hepatitis B. Hepatology 2000;32:847-51.
24. Buti M, Sanchez F, Cotrina M, et al. Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B. J Infect Dis 2001;183:1277-80.
25. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Anna Rev Immunol 1995;13:29-60.
26. Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell mediated cytotoxicity. Science 1994;265:528-30.
27. Guidotti LG, Ando K, Hobbs MV, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994;91:3764-8.
28. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996;4:25-36.
29. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-57.
30. Bjerrum OW, Bjerrum OJ, Borregaard N. Beta 2-microglobulin in neutrophils: An intragranular protein. J Immunol 1987;138:3913-7.
31. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy. Hepatology 2001;33:963-71.
32. Maini MK, Boni C, Lee CK, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000;191:1269-80.
33. Michalak TI, Hodgson PD, Churchill ND. Posttranscriptional inhibition 4 class I major histocompatibility complex presentation on hepatocytes and lymphoid cells in chronic woodchuck hepatitis virus infection. J Virol 2000;74:4483-94.
34. Tomita T, Yokosuka O, Tagawa M, et al. Decrease of wild type and precore mutant duck hepatitis B virus replication during lamivudine treatment in white Peking duck infected with the viruses. J Hepatol 2000;32:850-8.
35. Marinos G, Naoumov NV, Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology 1996;24:991-5.
36. Suri D, Schilling R, Lopes AR, et al. Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes. J Hepatol 2001;35:790-7.
37. Santantonio T, Niro GA, Sinisi E, et al. Lamivudine/interferon combination therapy in antiHbe positive chronic hepatitis B patients: A controlled pilot study. J Hepatol 2002;36:799-804.